NCT03361020Active, not recruiting
Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
While thoracic radiation therapy (TRT) has been a primary component in successful treatment of Hodgkin lymphoma, exposure to this treatment has been associated with significant cardiovascular, cerebrovascular, and pulmonary morbidity in long-term survivors. Survivors of Hodgkin lymphoma (HL) are also at risk for fatigue and excessive daytime sleepiness. Insufficient sleep is recognized as an important public health concern, and is associated with cardiovascular disease, diabetes, obesity, neurocognitive problems, and reduced quality of life and productivity. Survivors of HL, who are already at risk for cardiac and neurologic morbidity due to their treatment exposures, could face catastrophic cardiovascular and cerebrovascular events with the added risk associated with obstructive sleep apnea (OSA). The investigators propose to examine indices of sleep quality using polysomnography, and associated neurocognitive performance, brain MRI, and structure and strength of neck muscles in 220 long-term adult survivors of Hodgkin lymphoma treated with thoracic radiation. OBJECTIVES: 1. To estimate the prevalence of OSA in adult survivors of HL treated with thoracic radiation, and compare the frequency to community controls matched on age, gender, race and body mass index. 2. To identify specific therapeutic factors associated with OSA in adult survivors of HL treated with thoracic radiation. 3. To identify biomarkers of OSA in adult survivors of HL treated with thoracic radiation. 4. To examine associations between OSA and cardiac morbidity and brain integrity in the adult survivors of HL treated with thoracic radiation.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 434 (actual)
- First submitted
- 28 Nov 2017
- Start date
- 23 Jan 2018
- Primary completion date
- 31 Jul 2023
- Lead sponsor
- St. Jude Children's Research Hospital
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT03361020
What you commit to
- Study type: Observational
- Participants enrolled: 434
- From 23 Jan 2018 to the primary completion date, 31 Jul 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of cranial or total-body radiation therapy
- History of intrathecal Methotrexate, high-dose Methotrexate, or high-dose Cytarabine.
- History of head injury or diagnosis of a genetic disorder associated with neurocognitive impairment
- History of a neurodevelopmental disorder or birth complication associated with neurocognitive impairment
- History of congenital heart disease reported in the literature to be associated with neurocognitive status as determined by the PIs
- History of cranial, total-body or thoracic radiation therapy
- History of intrathecal Methotrexate, high-dose Methotrexate, or high-dose Cytarabine.
- History of head injury or diagnosis of a genetic disorder associated with neurocognitive impairment
- History of a neurodevelopmental disorder or birth complication associated with neurocognitive impairment
- History of congenital heart disease reported in the literature to be associated with neurocognitive status as determined by the PIs
- History of cancer
Other
- Currently pregnant
- Secondary central nervous system (CNS) neoplasm
- COMPARISON GROUP (CONTROL) ELIGIBILITY CRITERIA
- Currently pregnant
- 1st degree relative of a survivor included in the current study.
Who the study is looking for
- Current participant in the SJLIFE clinical trial ongoing at St. Jude Children's Research Hospital (SJCRH) and was treated with thoracic radiation for Hodgkin lymphoma
- Currently ≥ 18 years of age
- ≥ 5 years from original diagnosis
- Research participant is a sibling, parent, relative or friend of a current or former St. Jude patient
- Research participant must be at least 18 years of age at the time of the scheduled evaluation
Criteria the registry did not label
- HODGKIN LYMPHOMA SURVIVOR ELIGIBILITY CRITERIA
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Jude Children's Research Hospital Coordinator of this site? Confirm its status | Memphis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.